BNT-24003

BNT-24003 is a sublingual (oral dissolvable film) formulation developed by BioNxt Solutions for the treatment of rheumatoid arthritis. It is designed to improve patient comfort and compliance by providing a non-invasive alternative to pills or injections, particularly benefiting patients who have difficulty swallowing or require frequent dosing. The sublingual route allows for rapid dissolution and absorption directly into the bloodstream, potentially increasing bioavailability and enabling lower dosing with reduced side effects. As of March 2025, BNT-24003 remains in preclinical development. Its primary indication is rheumatoid arthritis, addressing unmet needs in symptom management for this chronic autoimmune disease[1][2][3][7].